These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 15578350)

  • 21. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
    Lalezari JP; Henry K; O'Hearn M; Montaner JS; Piliero PJ; Trottier B; Walmsley S; Cohen C; Kuritzkes DR; Eron JJ; Chung J; DeMasi R; Donatacci L; Drobnes C; Delehanty J; Salgo M;
    N Engl J Med; 2003 May; 348(22):2175-85. PubMed ID: 12637625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enfuvirtide: from basic investigations to current clinical use.
    Joly V; Jidar K; Tatay M; Yeni P
    Expert Opin Pharmacother; 2010 Nov; 11(16):2701-13. PubMed ID: 20977403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients.
    Lalezari JP; Patel IH; Zhang X; Dorr A; Hawker N; Siddique Z; Kolis SJ; Kinchelow T
    J Clin Virol; 2003 Oct; 28(2):217-22. PubMed ID: 12957192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector).
    Harris M; Joy R; Larsen G; Valyi M; Walker E; Frick LW; Palmatier RM; Wring SA; Montaner JS
    AIDS; 2006 Mar; 20(5):719-23. PubMed ID: 16514302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanism-based model of the pharmacokinetics of enfuvirtide, an HIV fusion inhibitor.
    Mohanty U; Dixit NM
    J Theor Biol; 2008 Apr; 251(3):541-51. PubMed ID: 18258267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enfuvirtide-PEG conjugate: A potent HIV fusion inhibitor with improved pharmacokinetic properties.
    Cheng S; Wang Y; Zhang Z; Lv X; Gao GF; Shao Y; Ma L; Li X
    Eur J Med Chem; 2016 Oct; 121():232-237. PubMed ID: 27240277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance to enfuvirtide, the first HIV fusion inhibitor.
    Greenberg ML; Cammack N
    J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.
    Stocker H; Kloft C; Plock N; Breske A; Kruse G; Herzmann C; Schulbin H; Kreckel P; Weber C; Goebel F; Roeling J; Staszewski S; Plettenberg A; Moecklinghoff C; Arastéh K; Kurowski M
    Antimicrob Agents Chemother; 2006 Feb; 50(2):667-73. PubMed ID: 16436725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Penetration of enfuvirtide, tenofovir, efavirenz, and protease inhibitors in the genital tract of HIV-1-infected men.
    Ghosn J; Chaix ML; Peytavin G; Rey E; Bresson JL; Goujard C; Katlama C; Viard JP; Tréluyer JM; Rouzioux C
    AIDS; 2004 Sep; 18(14):1958-61. PubMed ID: 15353984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.
    Aquaro S; D'Arrigo R; Svicher V; Perri GD; Caputo SL; Visco-Comandini U; Santoro M; Bertoli A; Mazzotta F; Bonora S; Tozzi V; Bellagamba R; Zaccarelli M; Narciso P; Antinori A; Perno CF
    J Antimicrob Chemother; 2006 Oct; 58(4):714-22. PubMed ID: 16891628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety and efficacy of enfuvirtide therapy for HIV infection in patients with hemophilia: a case series.
    Polizzotto MN; Street AM; Wright E
    Clin Infect Dis; 2007 Aug; 45(4):e39-41. PubMed ID: 17638184
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful desensitization to enfuvirtide after a hypersensitivity reaction in an HIV-1-infected man.
    DeSimone JA; Ojha A; Pathak R; Cohn J
    Clin Infect Dis; 2004 Nov; 39(10):e110-2. PubMed ID: 15546072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
    Su C; Melby T; DeMasi R; Ravindran P; Heilek-Snyder G
    J Clin Virol; 2006 Aug; 36(4):249-57. PubMed ID: 16765082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel form of amyloid deposited at the site of enfuvirtide injection.
    Naujokas A; Vidal CI; Mercer SE; Harp J; Kurtin PJ; Fox LP; Thompson MM
    J Cutan Pathol; 2012 Feb; 39(2):220-1; quiz 219. PubMed ID: 22264247
    [No Abstract]   [Full Text] [Related]  

  • 35. A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration.
    Loutfy MR; Harris M; Raboud JM; Antoniou T; Kovacs C; Shen S; Dufresne S; Smaill F; Rouleau D; Rachlis A; Gough K; Lalonde R; Tsoukas C; Trottier B; Walmsley SL; Montaner JS
    HIV Med; 2007 Oct; 8(7):427-32. PubMed ID: 17760734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.
    Deeks SG; Lu J; Hoh R; Neilands TB; Beatty G; Huang W; Liegler T; Hunt P; Martin JN; Kuritzkes DR
    J Infect Dis; 2007 Feb; 195(3):387-91. PubMed ID: 17205477
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.
    Bienvenu B; Krivine A; Rollot F; Pietri MP; Lebault V; Meritet JF; Guerin C; Spiridon G; Salmon D; Guillevin L; Lebon P; Launay O
    J Med Virol; 2006 Oct; 78(10):1312-7. PubMed ID: 16927284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy.
    Poveda E; Rodés B; Lebel-Binay S; Faudon JL; Jimenez V; Soriano V
    J Clin Virol; 2005 Dec; 34(4):295-301. PubMed ID: 16286053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction between enfuvirtide, an injectable fusion inhibitor, and niacin in an HIV-infected patient.
    Oates E; Dzintars K
    Ann Pharmacother; 2010 Dec; 44(12):2014-7. PubMed ID: 21045170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen.
    Cabrera C; Marfil S; García E; Martinez-Picado J; Bonjoch A; Bofill M; Moreno S; Ribera E; Domingo P; Clotet B; Ruiz L
    AIDS; 2006 Oct; 20(16):2075-80. PubMed ID: 17053353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.